Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128762

Cover Image

PUBLISHER: Data Bridge Market Research | PRODUCT CODE: 1128762

MEA Anthrax Treatment Market - Industry Trends and Forecast to 2029

PUBLISHED:
PAGES: 271 Pages
DELIVERY TIME: Inquiry
SELECT AN OPTION
PDF (Single User License) - Printable/Downloadable
USD 3500
PDF (Enterprise License) - Printable/Downloadable
USD 4200

Add to Cart

Middle East and Africa anthrax treatment market is projected to register a CAGR of 8.6% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2022 to 2029.

Market Segmentation:

Middle East and Africa Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others),Country (Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt and Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Some of the major factors contributing to the growth of the anthrax treatment market are:

Rising prevalence of anthrax infections

Increasing research funding and the development of novel therapies for anthrax treatment

Market Players:

The key market players for Middle East and Africa anthrax treatment market are listed below:

Alembic Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Zydus Group

Bayer AG

Pfizer Inc.

Lupin

Teva Pharmaceutical Industries Ltd.

ARISTO Pharmaceuticals Private Limited

TABLE OF CONTENTS

1 INTRODUCTION 74

  • 1.1 OBJECTIVES OF THE STUDY 74
  • 1.2 MARKET DEFINITION 74
  • 1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET 74
  • 1.4 LIMITATIONS 76
  • 1.5 MARKETS COVERED 76

2 MARKET SEGMENTATION 79

  • 2.1 MARKETS COVERED 79
  • 2.2 GEOGRAPHICAL SCOPE 80
  • 2.3 YEARS CONSIDERED FOR THE STUDY 81
  • 2.4 CURRENCY AND PRICING 81
  • 2.5 DBMR TRIPOD DATA VALIDATION MODEL 82
  • 2.6 MULTIVARIATE MODELLING 85
  • 2.7 PRODUCT SEGMENT LIFELINE CURVE 85
  • 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
  • 2.9 DBMR MARKET POSITION GRID 87
  • 2.10 MARKET APPLICATION COVERAGE GRID 88
  • 2.11 VENDOR SHARE ANALYSIS 89
  • 2.12 SECONDARY SOURCES 90
  • 2.13 ASSUMPTIONS 90

3 EXECUTIVE SUMMARY 91

4 PREMIUM INSIGHTS 95

  • 4.1 PESTEL ANALYSIS 96
  • 4.2 PORTER'S FIVE FORCES 97
  • 4.3 DEMOGRAPHIC TRENDS- 98
  • 4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 100
    • 4.4.1 INCIDENCE 100
    • 4.4.2 DEVELOPED COUNTRIES- 100
    • 4.4.3 DEVELOPING COUNTRIES- 100
  • 4.5 PATIENT ENROLMENT STRATEGIES- 102
  • 4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 106
  • 4.7 CURRENT STATE OF ANTHRAX VACCINES 108
  • 4.8 MIDDLE EAST & AFRICA ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 112
  • 4.9 MIDDLE EAST & AFRICA ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 113

5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEAR'S ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANY'S PIPELINE FOR ANTHRAX TREATMENT. 117

6 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET: REGULATIONS 119

7 MARKET OVERVIEW 123

  • 7.1 DRIVERS 125
    • 7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 125
    • 7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 125
    • 7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 126
    • 7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 126
  • 7.2 RESTRAINTS 127
    • 7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 127
    • 7.2.2 FALSE DATA INTERPRETATION 128
  • 7.3 OPPORTUNITIES 128
    • 7.3.1 RISING PRODUCT LAUNCHES 128
    • 7.3.2 RISING GOVERNMENT INITIATIVES 129
    • 7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 129
  • 7.4 CHALLENGES 130
    • 7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 130
    • 7.4.2 LACK OF SKILLED PROFESSIONALS 130

8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY TYPE 132

  • 8.1 OVERVIEW 133
  • 8.2 CUTANEOUS ANTHRAX 136
    • 8.2.1 ANTIBIOTICS 137
      • 8.2.1.1 BY DRUGS 137
        • 8.2.1.1.1 CIPROFLOXACIN 138
        • 8.2.1.1.2 LEVOFLOXACIN 138
        • 8.2.1.1.3 DOXYCYCLINE 138
        • 8.2.1.1.4 AMPICILLIN 138
        • 8.2.1.1.5 OTHERS 138
      • 8.2.1.2 BY PRODUCT TYPES 138
        • 8.2.1.2.1 GENERICS 138
        • 8.2.1.2.2 BRANDED 138
        • 8.2.1.2.2.1 CIPRO 139
        • 8.2.1.2.2.2 LEVO 139
        • 8.2.1.2.2.3 DOXY 139
        • 8.2.1.2.2.4 AMPICI 139
        • 8.2.1.2.2.5 OTHERS 139
    • 8.2.2 ANTITOXINS 140
      • 8.2.2.1 RAXIBACUMAB 140
      • 8.2.2.2 OBILTOXAXIMAB (ANTHIM) 140
      • 8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 140
      • 8.2.2.4 OTHERS 140
    • 8.2.3 VACCINES 141
      • 8.2.3.1 RAXIBACUMAB 141
    • 8.2.4 SURGERY 141
  • 8.3 PULMONARY ANTHRAX 141
    • 8.3.1 ANTIBIOTICS 142
      • 8.3.1.1 BY DRUGS 143
        • 8.3.1.1.1 CIPROFLOXACIN 143
        • 8.3.1.1.2 LEVOFLOXACIN 143
        • 8.3.1.1.3 DOXYCYCLINE 143
        • 8.3.1.1.4 AMPICILLIN 143
        • 8.3.1.1.5 OTHERS 143
      • 8.3.1.2 BY PRODUCT TYPES 144
        • 8.3.1.2.1 GENERICS 144
        • 8.3.1.2.2 BRANDED 144
        • 8.3.1.2.2.1 CIPRO 144
        • 8.3.1.2.2.2 LEVO 145
        • 8.3.1.2.2.3 DOXY 145
        • 8.3.1.2.2.4 AMPICI 145
        • 8.3.1.2.2.5 OTHERS 145
    • 8.3.2 ANTITOXINS 145
      • 8.3.2.1 RAXIBACUMAB 145
      • 8.3.2.2 OBILTOXAXIMAB (ANTHIM) 145
      • 8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 145
      • 8.3.2.4 OTHERS 146
    • 8.3.3 VACCINES 146
      • 8.3.3.1 RAXIBACUMAB 146
      • 8.3.3.2 SURGERY 146
  • 8.4 INTESTINAL ANTHRAX 146
    • 8.4.1 ANTIBIOTICS 148
      • 8.4.1.1 BY DRUGS 148
        • 8.4.1.1.1 CIPROFLOXACIN 148
        • 8.4.1.1.2 LEVOFLOXACIN 148
        • 8.4.1.1.3 DOXYCYCLINE 148
        • 8.4.1.1.4 AMPICILLIN 149
        • 8.4.1.1.5 OTHERS 149
      • 8.4.1.2 BY PRODUCT TYPES 149
        • 8.4.1.2.1 GENERICS 149
        • 8.4.1.2.2 BRANDED 149
        • 8.4.1.2.2.1 CIPRO 150
        • 8.4.1.2.2.2 LEVO 150
        • 8.4.1.2.2.3 DOXY 150
        • 8.4.1.2.2.4 AMPICI 150
        • 8.4.1.2.2.5 OTHERS 150
    • 8.4.2 ANTITOXINS 151
      • 8.4.2.1 RAXIBACUMAB 151
      • 8.4.2.2 OBILTOXAXIMAB (ANTHIM) 151
      • 8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 151
      • 8.4.2.4 OTHERS 151
    • 8.4.3 VACCINES 152
      • 8.4.3.1 RAXIBACUMAB 152
      • 8.4.3.2 SURGERY 152

9 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 153

  • 9.1 OVERVIEW 154
  • 9.2 PARENTERAL 157
  • 9.3 ORAL 157
  • 9.4 OTHERS 158

10 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY END USER 159

  • 10.1 OVERVIEW 160
  • 10.2 GOVERNMENT ORGANIZATION 163
  • 10.3 HOSPITALS 163
  • 10.4 ACADEMIC AND RESEARCH 164
  • 10.5 OTHERS 166

11 MIDDLE EAST & AFRICA VIRTUAL REALITY MARKET, BY GEOGRAPHY 167

  • 11.1 MIDDLE EAST AND AFRICA 168
    • 11.1.1 SOUTH AFRICA 185
    • 11.1.2 SAUDI ARABIA 194
    • 11.1.3 UAE 203
    • 11.1.4 EGYPT 212
    • 11.1.5 ISRAEL 221
    • 11.1.6 REST OF MIDDLE EAST AND AFRICA 230

12 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 231

  • 12.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 231

13 SWOT ANALYSIS 232

14 COMPANY PROFILE 233

  • 14.1 BAYER AG 233
    • 14.1.1 COMPANY SNAPSHOT 233
    • 14.1.2 REVENUE ANALYSIS 233
    • 14.1.3 COMPANY SHARE ANALYSIS 234
    • 14.1.4 PRODUCT PORTFOLIO 234
    • 14.1.5 RECENT DEVELOPMENTS 234
  • 14.2 PFIZER INC. 235
    • 14.2.1 COMPANY SNAPSHOT 235
    • 14.2.2 REVENUE ANALYSIS 235
    • 14.2.3 COMPANY SHARE ANALYSIS 236
    • 14.2.4 PRODUCT PORTFOLIO 236
    • 14.2.5 RECENT DEVELOPMENTS 236
  • 14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 237
    • 14.3.1 COMPANY SNAPSHOT 237
    • 14.3.2 REVENUE ANALYSIS 237
    • 14.3.3 COMPANY SHARE ANALYSIS 238
    • 14.3.4 PRODUCT PORTFOLIO 238
    • 14.3.5 RECENT DEVELOPMENT 238
  • 14.4 SANOFI 239
    • 14.4.1 COMPANY SNAPSHOT 239
    • 14.4.2 REVENUE ANALYSIS 239
    • 14.4.3 COMPANY SHARE ANALYSIS 240
    • 14.4.4 PRODUCT PORTFOLIO 240
    • 14.4.5 RECENT DEVELOPMENTS 240
  • 14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 241
    • 14.5.1 COMPANY SNAPSHOT 241
    • 14.5.2 REVENUE ANALYSIS 241
    • 14.5.3 PRODUCT PORTFOLIO 242
    • 14.5.4 RECENT DEVELOPMENT 242
  • 14.6 ALEMBIC PHARMACEUTICALS LIMITED 243
    • 14.6.1 COMPANY SNAPSHOT 243
    • 14.6.2 PRODUCT PORTFOLIO 243
    • 14.6.3 RECENT DEVELOPMENTS 243
  • 14.7 ALTIMMUNE 244
    • 14.7.1 COMPANY SNAPSHOT 244
    • 14.7.2 REVENUE ANALYSIS 244
    • 14.7.3 PRODUCT PORTFOLIO 245
    • 14.7.4 RECENT DEVELOPMENTS 245
  • 14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 246
    • 14.8.1 COMPANY SNAPSHOT 246
    • 14.8.2 PRODUCT PORTFOLIO 246
    • 14.8.3 RECENT DEVELOPMENTS 246
  • 14.9 BLUEWILLOW BIOLOGICS. 247
    • 14.9.1 COMPANY SNAPSHOT 247
    • 14.9.2 PRODUCT PORTFOLIO 247
    • 14.9.3 RECENT DEVELOPMENTS 247
  • 14.10 DEINOVE 248
    • 14.10.1 COMPANY SNAPSHOT 248
    • 14.10.2 REVENUE ANALYSIS 248
    • 14.10.3 PRODUCT PORTFOLIO 249
    • 14.10.4 RECENT DEVELOPMENTS 249
  • 14.11 EMERGENT 250
    • 14.11.1 COMPANY SNAPSHOT 250
    • 14.11.2 REVENUE ANALYSIS 250
    • 14.11.3 PRODUCT PORTFOLIO 251
    • 14.11.4 RECENT DEVELOPMENTS 251
  • 14.12 ELUSYS THERAPEUTICS INC. 252
    • 14.12.1 COMPANY SNAPSHOT 252
    • 14.12.2 PRODUCT PORTFOLIO 252
    • 14.12.3 RECENT DEVELOPMENTS 252
  • 14.13 GC BIOPHARMA CORP. 253
    • 14.13.1 COMPANY SNAPSHOT 253
    • 14.13.2 REVENUE ANALYSIS 253
    • 14.13.3 PRODUCT PORTFOLIO 254
    • 14.13.4 RECENT DEVELOPMENTS 254
  • 14.14 INDOCO REMEDIES LTD. 255
    • 14.14.1 COMPANY SNAPSHOT 255
    • 14.14.2 REVENUE ANALYSIS 255
    • 14.14.3 PRODUCT PORTFOLIO 256
    • 14.14.4 RECENT DEVELOPMENTS 256
  • 14.15 INTEGRATED BIOTHERAPEUTICS, INC. 257
    • 14.15.1 COMPANY SNAPSHOT 257
    • 14.15.2 PRODUCT PORTFOLIO 257
    • 14.15.3 RECENT DEVELOPMENTS 257
  • 14.16 LUPIN. 258
    • 14.16.1 COMPANY SNAPSHOT 258
    • 14.16.2 REVENUE ANALYSIS 258
    • 14.16.3 PRODUCT PORTFOLIO 259
    • 14.16.4 RECENT DEVELOPMENTS 259
  • 14.17 PARATEK PHARMACEUTICALS, INC. 260
    • 14.17.1 COMPANY SNAPSHOT 260
    • 14.17.2 REVENUE ANALYSIS 260
    • 14.17.3 PRODUCT PORTFOLIO 261
    • 14.17.4 RECENT DEVELOPMENTS 261
  • 14.18 PORTON BIOPHARMA 262
    • 14.18.1 COMPANY SNAPSHOT 262
    • 14.18.2 PRODUCT PORTFOLIO 262
    • 14.18.3 RECENT DEVELOPMENTS 262
  • 14.19 SOLIGENIX 263
    • 14.19.1 COMPANY SNAPSHOT 263
    • 14.19.2 REVENUE ANALYSIS 263
    • 14.19.3 PRODUCT PORTFOLIO 264
    • 14.19.4 RECENT DEVELOPMENTS 264
  • 14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 265
    • 14.20.1 COMPANY SNAPSHOT 265
    • 14.20.2 REVENUE ANALYSIS 265
    • 14.20.3 PRODUCT PORTFOLIO 266
    • 14.20.4 RECENT DEVELOPMENTS 266
  • 14.21 ZYDUS GROUP 267
    • 14.21.1 COMPANY SNAPSHOT 267
    • 14.21.2 REVENUE ANALYSIS 267
    • 14.21.3 PRODUCT PORTFOLIO 268
    • 14.21.4 RECENT DEVELOPMENTS 268

15 QUESTIONNAIRE 269

16 RELATED REPORTS 271

LIST OF TABLES

  • TABLE 1 POPULATION AT RISK (IN MILLIONS) BY REGION, LAND USE AND OCCUPATIONAL EXPOSURE, 2020- 51
  • TABLE 2 VACCINES IN DEVELOPMENT 60
  • TABLE 3 ANTIBIOTIC CONSUMPTION ESTIMATES BY GBD SUPER-REGION AND GBD REGION, FOR THE YEAR 2018- 67
  • TABLE 4 COUNTRY DATA OF ANTIBIOTICS CONSUMPTION- 68
  • TABLE 5 RECENT M&A IN ANTHRAX MARKET- 69
  • TABLE 6 ANTIBIOTICS MEDICINES 72
  • TABLE 7 FDA REQUIRES THE FOLLOWING SCENARIO BEFORE A DRUG IS APPROVED 74
  • TABLE 8 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, TYPE, 2020-2029 (USD MILLION) 87
  • TABLE 9 MIDDLE EAST & AFRICA CUTANEOUS ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 88
  • TABLE 10 MIDDLE EAST & AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 89
  • TABLE 11 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 89
  • TABLE 12 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 89
  • TABLE 13 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 90
  • TABLE 14 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 91
  • TABLE 15 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 92
  • TABLE 16 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 93
  • TABLE 17 MIDDLE EAST & AFRICA PULMONARY ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 94
  • TABLE 18 MIDDLE EAST & AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 94
  • TABLE 19 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 94
  • TABLE 20 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 95
  • TABLE 21 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 22 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 96
  • TABLE 23 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 97
  • TABLE 24 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 98
  • TABLE 25 MIDDLE EAST & AFRICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 99
  • TABLE 26 MIDDLE EAST & AFRICA INTESTINAL ANTHRAX IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 99
  • TABLE 27 MIDDLE EAST & AFRICA ANTIBIOTICS IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 100
  • TABLE 28 MIDDLE EAST & AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 100
  • TABLE 29 MIDDLE EAST & AFRICA BY PRODUCT TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 101
  • TABLE 30 MIDDLE EAST & AFRICA BRANDED IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 102
  • TABLE 31 MIDDLE EAST & AFRICA ANTITOXIN IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 103
  • TABLE 32 MIDDLE EAST & AFRICA VACCINES IN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 104
  • TABLE 33 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 108
  • TABLE 34 MIDDLE EAST & AFRICA PARENTERAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 109
  • TABLE 35 MIDDLE EAST & AFRICA ORAL IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 36 MIDDLE EAST & AFRICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 110
  • TABLE 37 MIDDLE EAST & AFRICA ANTHRAX TREATMENT MARKET, BY END USER, 2020-2029 (USD MILLION) 114
  • TABLE 38 MIDDLE EAST & AFRICA GOVERNMENT ORGANIZATION IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 115
  • TABLE 39 MIDDLE EAST & AFRICA HOSPITALS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 116
  • TABLE 40 MIDDLE EAST & AFRICA ACADEMIC AND RESEARCH IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 117
  • TABLE 41 MIDDLE EAST & AFRICA OTHERS IN ANTHRAX TREATMENT MARKET, BY REGION, 2020-2029 (USD MILLION) 118
  • TABLE 42 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY COUNTRY, 2020-2029 (USD MILLION) 124
  • TABLE 43 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 44 MIDDLE EAST AND AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 124
  • TABLE 45 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 46 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 125
  • TABLE 47 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 125
  • TABLE 48 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 125
  • TABLE 49 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 50 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 126
  • TABLE 51 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 126
  • TABLE 52 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 126
  • TABLE 53 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 127
  • TABLE 54 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 127
  • TABLE 55 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 127
  • TABLE 56 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 57 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 128
  • TABLE 58 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 128
  • TABLE 59 MIDDLE EAST AND AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 60 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 128
  • TABLE 61 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 62 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 129
  • TABLE 63 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 129
  • TABLE 64 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 129
  • TABLE 65 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 130
  • TABLE 66 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 130
  • TABLE 67 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 130
  • TABLE 68 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 69 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 131
  • TABLE 70 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 131
  • TABLE 71 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 131
  • TABLE 72 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 132
  • TABLE 73 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 132
  • TABLE 74 MIDDLE EAST AND AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 75 MIDDLE EAST AND AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 132
  • TABLE 76 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 77 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 133
  • TABLE 78 MIDDLE EAST AND AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 133
  • TABLE 79 MIDDLE EAST AND AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 133
  • TABLE 80 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 134
  • TABLE 81 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 134
  • TABLE 82 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 134
  • TABLE 83 MIDDLE EAST AND AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 84 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 135
  • TABLE 85 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 135
  • TABLE 86 MIDDLE EAST AND AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 135
  • TABLE 87 MIDDLE EAST AND AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 136
  • TABLE 88 MIDDLE EAST AND AFRICA BRANDED TYPES ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (ASP) 136
  • TABLE 89 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 136
  • TABLE 90 MIDDLE EAST AND AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION) 136
  • TABLE 91 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 92 SOUTH AFRICA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 93 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 94 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 137
  • TABLE 95 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 138
  • TABLE 96 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 97 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 138
  • TABLE 98 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 139
  • TABLE 99 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 100 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 139
  • TABLE 101 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 139
  • TABLE 102 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 139
  • TABLE 103 SOUTH AFRICA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 104 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 105 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 140
  • TABLE 106 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 140
  • TABLE 107 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 108 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 109 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 141
  • TABLE 110 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 141
  • TABLE 111 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 142
  • TABLE 112 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 113 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 142
  • TABLE 114 SOUTH AFRICA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 115 SOUTH AFRICA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 142
  • TABLE 116 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 143
  • TABLE 117 SOUTH AFRICA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 143
  • TABLE 118 SOUTH AFRICA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 143
  • TABLE 119 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 143
  • TABLE 120 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 144
  • TABLE 121 SOUTH AFRICA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 122 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 144
  • TABLE 123 SOUTH AFRICA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 144
  • TABLE 124 SOUTH AFRICA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 144
  • TABLE 125 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 145
  • TABLE 126 SOUTH AFRICA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION) 145
  • TABLE 127 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 128 SAUDI ARABIA CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 129 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 130 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 146
  • TABLE 131 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 147
  • TABLE 132 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 147
  • TABLE 133 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 147
  • TABLE 134 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 148
  • TABLE 135 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 136 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 148
  • TABLE 137 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 148
  • TABLE 138 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 148
  • TABLE 139 SAUDI ARABIA PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 140 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 141 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 149
  • TABLE 142 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 149
  • TABLE 143 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 144 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 145 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 150
  • TABLE 146 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 150
  • TABLE 147 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 151
  • TABLE 148 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 149 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 151
  • TABLE 150 SAUDI ARABIA INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 151 SAUDI ARABIA ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 151
  • TABLE 152 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 153 SAUDI ARABIA BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 152
  • TABLE 154 SAUDI ARABIA BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 155 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 152
  • TABLE 156 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 153
  • TABLE 157 SAUDI ARABIA ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 153
  • TABLE 158 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 153
  • TABLE 159 SAUDI ARABIA VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 153
  • TABLE 160 SAUDI ARABIA BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 153
  • TABLE 161 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 154
  • TABLE 162 SAUDI ARABIA ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION) 154
  • TABLE 163 U.A.E ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 164 U.A.E CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 165 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 166 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 155
  • TABLE 167 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 156
  • TABLE 168 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 169 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 156
  • TABLE 170 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 156
  • TABLE 171 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 157
  • TABLE 172 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 157
  • TABLE 173 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 157
  • TABLE 174 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 157
  • TABLE 175 U.A.E PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 157
  • TABLE 176 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 177 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 178 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 158
  • TABLE 179 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 158
  • TABLE 180 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 159
  • TABLE 181 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 159
  • TABLE 182 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 159
  • TABLE 183 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 159
  • TABLE 184 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 185 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 160
  • TABLE 186 U.A.E INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 187 U.A.E ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 188 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 160
  • TABLE 189 U.A.E BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 161
  • TABLE 190 U.A.E BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 191 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 161
  • TABLE 192 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 161
  • TABLE 193 U.A.E ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 194 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 162
  • TABLE 195 U.A.E VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 162
  • TABLE 196 U.A.E BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 162
  • TABLE 197 U.A.E ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 162
  • TABLE 198 U.A.E ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION) 163
  • TABLE 199 EGYPT ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 200 EGYPT CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 201 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 202 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 164
  • TABLE 203 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 165
  • TABLE 204 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 165
  • TABLE 205 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 165
  • TABLE 206 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 165
  • TABLE 207 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 208 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 166
  • TABLE 209 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 210 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 166
  • TABLE 211 EGYPT PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 166
  • TABLE 212 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 167
  • TABLE 213 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 167
  • TABLE 214 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 167
  • TABLE 215 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 167
  • TABLE 216 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 217 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 168
  • TABLE 218 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 168
  • TABLE 219 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 168
  • TABLE 220 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 169
  • TABLE 221 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 169
  • TABLE 222 EGYPT INTESTINAL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 169
  • TABLE 223 EGYPT ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 169
  • TABLE 224 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 169
  • TABLE 225 EGYPT BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 170
  • TABLE 226 EGYPT BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 227 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 170
  • TABLE 228 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 170
  • TABLE 229 EGYPT ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 171
  • TABLE 230 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 171
  • TABLE 231 EGYPT VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 171
  • TABLE 232 EGYPT BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 171
  • TABLE 233 EGYPT ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION) 171
  • TABLE 234 EGYPT ANTHRAX TREATMENT MARKET, BY END USERS, 2020-2029 (USD MILLION) 172
  • TABLE 235 ISRAEL ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 173
  • TABLE 236 ISRAEL CUTANEOUS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 173
  • TABLE 237 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 173
  • TABLE 238 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 173
  • TABLE 239 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 174
  • TABLE 240 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 241 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 174
  • TABLE 242 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 174
  • TABLE 243 ISRAEL ANTITOXIN ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 244 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 175
  • TABLE 245 ISRAEL VACCINE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 246 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 175
  • TABLE 247 ISRAEL PULMONARY ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 175
  • TABLE 248 ISRAEL ANTIBIOTICS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 249 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 250 ISRAEL BY DRUGS ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (UNITS) 176
  • TABLE 251 ISRAEL BY PRODUCT TYPE ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 176
  • TABLE 252 ISRAEL BRANDED ANTHRAX TREATMENT MARKET, BY TYPE, 2020-2029 (USD MILLION) 177
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!